Abbvie (ABBV) Stock
Large pharmaceutical company with strong cash flow and dividend. Here's the price, business snapshot, and what's worth knowing about Abbvie in October 2026.
AbbVie Inc (ABBV) is a large-cap biopharmaceutical company known for established prescription medicines and an expanding pipeline. Historically driven by a few high-revenue products, AbbVie has sought to diversify through R&D, new product launches and acquisitions. The company generates significant free cash flow and is a regular dividend payer, which may attract income-focused investors. Key considerations for potential investors include patent and competition risks (including biosimilars), the outcome of clinical trials, regulatory approvals and pricing pressure in major markets. Market-cap scale and a broad geographic footprint can offer resilience, but revenues can be volatile around patent cliffs and product lifecycle events. This summary is for general educational purposes only and is not personal investment advice; investors should assess their own risk tolerance, time horizon and seek independent advice before acting. Past performance is not a guide to future results.
Why It’s Moving
AbbVie Eyes Major Catalysts Ahead of Q3 Earnings as Pipeline Wins and Dividend Strength Drive Momentum
- The U.S. FDA approved a new subcutaneous induction regimen for SKYRIZI® for Crohn's disease, expanding treatment options and reinforcing the drug's market position.
- Phase 3 INTREPID trial results showed lutikizumab significantly improved symptoms in hidradenitis suppurativa patients, meeting primary endpoints and supporting future regulatory filings.
- Options pricing implies a roughly 5% move upon the upcoming Q3 earnings report, while shares remain up over 28% year-to-date amid strong dividend growth narratives.
AbbVie Eyes Major Catalysts Ahead of Q3 Earnings as Pipeline Wins and Dividend Strength Drive Momentum
- The U.S. FDA approved a new subcutaneous induction regimen for SKYRIZI® for Crohn's disease, expanding treatment options and reinforcing the drug's market position.
- Phase 3 INTREPID trial results showed lutikizumab significantly improved symptoms in hidradenitis suppurativa patients, meeting primary endpoints and supporting future regulatory filings.
- Options pricing implies a roughly 5% move upon the upcoming Q3 earnings report, while shares remain up over 28% year-to-date amid strong dividend growth narratives.
Sixth Month Growth Performance
When is the next earnings date for AbbVie (ABBV)?
ABBV is scheduled to release its next earnings report on October 30, 2026, before the market opens. This upcoming announcement will cover the company's financial performance for the third quarter of 2026. The confirmed date aligns with the typical reporting cycle observed in recent quarters, providing investors with a clear timeline for this update.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AbbVie's stock, expecting it to rise to a target price of $242.22.
Financial Health
AbbVie is performing well financially with strong revenue, profits, and cash flow generation.
Dividend
AbbVie's dividend yield of 2.39% offers moderate returns for investors seeking income. If you invested $1000 you would be paid $23.90 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Large-cap pharma value
Generates strong cash flows and has a track record of dividends, which may suit income-oriented allocations — though yields and share performance can fluctuate.
Pipeline and innovation
New drug approvals and successful trials can drive growth, but R&D outcomes are uncertain and clinical setbacks are possible.
Global market exposure
A broad geographic footprint diversifies revenue sources, while differing regulations and pricing environments create both opportunity and risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
